All were from isocitrate dehydrogenase (IDH)–wild-type GBM, 23 were from treatment naïve tumors, and 2 were from recurrent GBMs initially treated by surgical resection and adjuvant radiotherapy and chemotherapy. This evidence concerns the gene IDH3A and glioblastoma.